Is BAX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Baxter International (BAX) rests on Margin and operational turnaround: New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. Revenue (TTM, continuing ops) is ~$10.7B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Whether BAX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies. The investment picture is a turnaround, not a growth story. Q1 2026 sales from continuing operations were about $2.7 billion (up roughly 3% reported, down about 1% organic), adjusted EPS beat expectations at $0.36, but GAAP results showed a small loss and adjusted operating margin compressed sharply on special charges, a Novum IQ pump shipment hold, supply constraints, and inflation. New CEO Andrew Hider, who joined in late 2025 with a lean-manufacturing reputation, is focused on stabilizing execution and improving margins while the company works to bring leverage down. The stock trades at a modest multiple relative to peers, reflecting both the balance-sheet overhang and skepticism about how quickly the turnaround delivers.
What's the case for buying BAX?
1. Margin and operational turnaround
New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. Management describes early progress in stabilizing the business and strengthening execution. Success here is the central lever for the equity.
2. Deleveraging after the Vantive sale
Baxter used proceeds from the roughly $3.8 billion Vantive kidney care divestiture to cut debt, but long-term debt still sits around $8.6 billion against about $2 billion of cash. Management has named debt paydown as the immediate priority for excess cash until leverage reaches roughly 3x, which would free up financial flexibility over time.
3. Infusion systems and connected-care portfolio
The Novum IQ pump platform has driven double-digit US infusion-systems gains when shipping normally, and the Hillrom connected-care hardware adds recurring hospital exposure. Resolving the Novum LVP shipment hold and realizing Hillrom synergies are key to reaccelerating growth.
4. Essential hospital supply demand
Baxter sells mission-critical, high-volume consumables (IV fluids, injectables, sets) that hospitals need regardless of the economic cycle, giving the base business durable, defensive demand. That recurring nature underpins revenue even as the company reshapes its portfolio.
What are the risks to BAX?
The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.
How is BAX valued? (as of July 2026)
Snapshot for BAX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM, continuing ops): ~$10.7B
- Q1 2026 sales: ~$2.7B
- Q1 2026 adjusted EPS: ~$0.36
- Market cap: ~$11.5B
- Long-term debt: ~$8.6B
- Dividend (quarterly): ~$0.01 (cut Jan 2026)
Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.
How do you decide if BAX is a buy?
Rather than asking whether BAX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BAX indirectly through an index or sector ETF before adding more.
For the full picture, see the BAX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BAX against your real portfolio and see your actual exposure before deciding.
The bottom line on BAX
The bottom line: Baxter International's story right now is Margin and operational turnaround, with revenue (ttm, continuing ops) at ~$10.7B. If you believe that narrative continues, the call is about sizing BAX sensibly and checking overlap with what you own; if you doubt it (the risk: the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on BAX
- BAX stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- BAX stock forecast (the drivers and risks shaping the outlook)
- Does BAX pay a dividend?
Build a basket around BAX with Walnut
Use Baxter International as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BAX a good stock to buy right now?
+
The case for Baxter International right now is Margin and operational turnaround, with revenue (ttm, continuing ops) at ~$10.7B. If you believe that thesis holds, BAX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Baxter International do?
+
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs,
What are the main risks of BAX?
+
The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.
What does Baxter International do?
+
Baxter makes essential hospital and critical-care products: IV solutions, infusion pumps, premixed and injectable drugs, surgical sealants, and connected-care hardware from its Hillrom business. Its customers are hospitals and health systems worldwide.
What happened to Baxter's kidney care business?
+
Baxter separated its Kidney Care segment, rebranded Vantive, and sold it to the Carlyle Group for roughly $3.8 billion. Vantive is now a standalone vital-organ-therapy company, and Baxter used proceeds to reduce debt and focus on hospital products.
Is Baxter profitable?
+
On an adjusted basis Baxter remains profitable (Q1 2026 adjusted EPS was about $0.36), but GAAP results have swung to small losses on special charges. Adjusted operating margin compressed recently due to a pump shipment hold, supply constraints, and inflation.
How much debt does Baxter carry?
+
Baxter had roughly $8.6 billion in long-term debt and about $2 billion in cash as of Q1 2026. Management has made debt paydown the immediate priority for excess cash until leverage falls to around 3x.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BAX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.